Dusigitumab

Drug Profile

Dusigitumab

Alternative Names: MEDI-573

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor I inhibitors; Insulin-like growth factor II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • No development reported Hepatocellular carcinoma; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 24 Sep 2015 No recent reports of development identified - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 24 Sep 2015 No recent reports of development identified - Phase-I/II for Hepatocellular carcinoma (Combination therapy, Inoperable/Unresectable, Metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top